A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: protection of African green monkeys from COVID-19 disease
Journal of Virology · 2024
DOI: 10.1128/jvi.01762-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, 2024. Verfasst von Sham Nambulli und 19 weiteren Autor:innen. Beteiligte Einrichtung: Center for Vaccine Research, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Spike Glycoprotein, Coronavirus, SARS-CoV-2, COVID-19, Measles virus. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NIAID NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged at the end of 2019 and is responsible for the largest human pandemic in 100 years. Thirty-four vaccines are currently approved for use worldwide, and approximately 67% of the world population has received a complete primary series of one, yet countries are dealing with new waves of infections, variant viruses continue to emerge, and breakthrough infections are frequent secondary to waning immunity. Here, we evaluate a measles virus (MV)-vectored vaccine expressing a stabilized prefusion SARS-CoV-2 spike (S) protein (MV-ATU3-S2PΔF2A; V591) with demonstrated immunogenicity in mouse models (see companion article [J. Brunet, Z. Choucha, M. Gransagne, H. Tabbal, M.-W. Ku et al., J Virol 98:e01693-23, 2024, https://doi.org/10.1128/jvi.01693-23 ]) in an established African green monkey model of disease. Animals were vaccinated with V591 or the control vaccine (an equivalent MV-vectored vaccine with an irrelevant antigen) intramuscularly using a prime/boost schedule, followed by challenge with an early pandemic isolate of SARS-CoV-2 at 56 days post-vaccination. Pre-challenge, only V591-vaccinated animals developed S-specific antibodies that had virus-neutralizing activity as well as S-specific T cells. Following the challenge, V591-vaccinated animals had lower infectious virus and viral (v) RNA loads in mucosal secretions and stopped shedding virus in these secretions earlier. vRNA loads were lower in these animals in respiratory and gastrointestinal tract tissues at necropsy. This correlated with a lower disease burden in the lungs as quantified by PET/CT at early and late time points post-challenge and by pathological analysis at necropsy. IMPORTANCE Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the largest human pandemic in 100 years. Even though vaccines are currently available, countries are dealing with new waves of infections, variant viruses continue to emerge, breakthrough infections are frequent, and vaccine hesitancy persists. This study uses a safe and effective measles vaccine as a platform for vaccination against SARS-CoV-2. The candidate vaccine was used to vaccinate African green monkeys (AGMs). All vaccinated AGMs developed robust antigen-specific immune responses. After challenge, these AGMs produced less virus in mucosal secretions, for a shorter period, and had a reduced disease burden in the lungs compared to control animals. At necropsy, lower levels of viral RNA were detected in tissue samples from vaccinated animals, and the lungs of these animals lacked the histologic hallmarks of SARS-CoV-2 disease observed exclusively in the control AGMs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Vaccine Research, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
- Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
- Département de Santé Globale, Institut Pasteur, Université de Paris Cite, Paris, France.
- Division of Pediatric Infectious Disease, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
- National Emerging Infectious Diseases Laboratories, Boston University School of Medicine, Boston, Massachusetts, USA.
- Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts, USA.
ORCID-Profile: Nicolas Escriou, Linda J Rennick, Anita K McElroy, Dominique J Barbeau, Nicholas A Crossland, JoAnne L Flynn, Christiane Gerke, Amy L Hartman, W Paul Duprex
Förderung
- NIH HHS
- NIAID NIH HHS
- NINDS NIH HHS
- The Chancellor's Office, University of Pittsburgh
- The Henry Hilleman Family Foundation
- Themis Bioscience GmbH, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
- HHS | NIH | National Institute of Allergy and Infectious Diseases
- HHS | NIH | NIH Office of the Director
Zitieren
APA
Nambulli, S., Escriou, N., Rennick, L. J., Demers, M. J., Tilston-Lunel, N. L., McElroy, A. K., Barbeau, D. J., Crossland, N. A., Hoehl, R. M., Schrauf, S., White, A. G., Borish, H. J., Tomko, J. A., Frye, L. J., Scanga, C. A., Flynn, J. L., Martin, A., Gerke, C., Hartman, A. L., & Duprex, W. P. (2024). A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: protection of African green monkeys from COVID-19 disease. Journal of Virology. https://doi.org/10.1128/jvi.01762-23
Vancouver
Nambulli S, Escriou N, Rennick LJ, Demers MJ, Tilston-Lunel NL, McElroy AK, et al. A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: protection of African green monkeys from COVID-19 disease. Journal of Virology. 2024. doi:10.1128/jvi.01762-23
BibTeX
@article{Nambulli2024,
author = {Nambulli, Sham and Escriou, Nicolas and Rennick, Linda J and Demers, Matthew J and Tilston-Lunel, Natasha L and McElroy, Anita K and Barbeau, Dominique J and Crossland, Nicholas A and Hoehl, Ryan M and Schrauf, Sabrina and White, Alexander G and Borish, H Jacob and Tomko, Jaime A and Frye, Lonnie J and Scanga, Charles A and Flynn, JoAnne L and Martin, Annette and Gerke, Christiane and Hartman, Amy L and Duprex, W Paul},
title = {A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: protection of African green monkeys from COVID-19 disease},
journal = {Journal of Virology},
year = {2024},
doi = {10.1128/jvi.01762-23}
}
EUVIMED